MoonLake Immunotherapeutics MLTX Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's unrealized gains (losses) on available-for-sale securities?
- MoonLake Immunotherapeutics (MLTX) reported unrealized gains (losses) on available-for-sale securities of $77K in Q1 2026.
- How has MoonLake Immunotherapeutics's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- MoonLake Immunotherapeutics's unrealized gains (losses) on available-for-sale securities increased by 102.8% year-over-year, from -$2.76M to $77K.
- What is the long-term trend for MoonLake Immunotherapeutics's unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2022 to 2025), MoonLake Immunotherapeutics's unrealized gains (losses) on available-for-sale securities has grown at a 262.1% compound annual growth rate (CAGR), from $390.75K to -$5.12M.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric captures the unrealized changes in the fair value of available-for-sale debt securities held by the company. These fluctuations reflect market-driven price movements that have not yet been realized through a sale. It provides insight into the volatility and performance of the company's treasury or investment portfolio.